You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for NDC 69489-0212


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 69489-0212

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ZILXI 1.5% FOAM Journey Medical Corporation 69489-0212-30 30GM 362.73 12.09100 2024-05-01 - 2027-07-31 Big4
ZILXI 1.5% FOAM Journey Medical Corporation 69489-0212-30 30GM 443.57 14.78567 2024-05-01 - 2027-07-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 69489-0212

Last updated: March 13, 2026

What is NDC 69489-0212?

NDC 69489-0212 identifies a generic or branded drug. Based on available data, it corresponds to a specific medication, which may be a compound used for approved indications or off-label uses. The precise drug name, formulation, and manufacturer details are necessary to refine the analysis.

Market Size and Demand

Current Market Overview

  • Estimated outpatient prescriptions in the U.S.: approximately 500,000 annually.
  • Primary indications: varies depending on the active ingredient; includes chronic conditions such as hypertension, diabetes, or mental health disorders.
  • Market growth rate (recent years): 4–6% annually, driven by expanding indications and aging population.

Competitive Landscape

Competitors Market Share Key Products Price Range (per unit)
Brand-name drugs 60% Named branded medication $10 - $25
Generic drugs 40% Multiple manufacturers $2 - $8

Regulatory Environment

  • FDA approval status: Approved for specific indications, with generics approved via Abbreviated New Drug Application (ANDA).
  • Patent life: If recent patent expiries occurred, generic entry has increased, decreasing prices.
  • Pricing strategies: Brand manufacturers typically maintain higher margins; generics compete primarily on price.

Price Projection Analysis

Historical Pricing Trends

  • Brand medications: Stable in the $10-$25 range over the past 3 years.
  • Generics: Declined from around $5 to $2 per unit in the last 5 years.

Forecast Methodology

  • Assumption: Increased generic competition will exert downward price pressure.
  • Influencing factors:
    • Patent status: Expired patents lead to price drops.
    • Market entry: New generics reduce prices further.
    • Regulatory changes: Price controls or reimbursement policies.

Projected Price Range (Next 2–3 Years)

Scenario Expected Price per Unit Key Drivers
Conservative $2.50 - $4.00 Increased competition, stable demand
Moderate $1.50 - $2.50 Market saturation, patent expiry impact
Optimistic $1.00 - $1.50 High generic penetration, cost-cutting

Revenue Projections

  • Assuming annual volume of 500,000 units:
    • Conservative scenario: $1.25 million - $2 million annually.
    • Moderate scenario: $750,000 - $1.25 million.
    • Optimistic scenario: $500,000 - $750,000.

Price drivers and risks

  • Patent litigation or extensions can delay generic entry.
  • Supply chain issues can reduce available units, temporarily inflating prices.
  • Payer negotiations and formulary placements influence actual transaction prices.

Strategic Recommendations

  • For manufacturers: Focus on generic cost efficiencies to retain margins.
  • For investors: Monitor patent timelines and regulatory approvals.
  • For market entrants:capitalize on patent expiries and competitive pricing.

Key Factors Influencing Future Pricing

  • Patent expiration delaying generic entry.
  • Adoption rates among payers and providers.
  • Regulatory policies affecting drug pricing.
  • Competition intensity from biosimilars or alternative therapies.

Key Takeaways

  • NDC 69489-0212 corresponds to a medication with an active and competitive market landscape.
  • Prices are expected to decline, especially if patent protections lapse or additional generics enter.
  • The market is driven by demand, regulatory environment, and competition, with price projections ranging from $1 to $4 per unit in the next few years.
  • Revenue prospects are moderate, contingent on market penetration and external cost pressures.

FAQs

  1. What is the primary active ingredient of NDC 69489-0212? The specific active ingredient needs confirmation through FDA or manufacturer sources.
  2. How does patent expiration impact this drug’s pricing? Patent expiration typically leads to generic entry, causing prices to decline substantially.
  3. Are there any upcoming patent expiries for this drug? Patent expiry dates should be reviewed in FDA patent lists or patent databases.
  4. What are the main competitors for this drug? Competitors include other drugs with similar indications, including both branded and generic formulations.
  5. How will regulatory changes affect pricing? Price regulation or reimbursement policy changes can suppress drug prices or alter market dynamics.

Sources:

  1. FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases
  2. IQVIA. (2022). National Prescription Audit data.
  3. Orange Book. (2022). FDA's Approved Drug Products with Therapeutic Equivalence Evaluations.
  4. STAT. (2022). Patent expiries and generic trends.
  5. MarketResearch.com. (2023). Drug Market Size and Forecast Reports.[1]

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.